use of these models requires the development and application of methods to quantitatively measure intracranial tumor growth.
I N ONCOLOGY RESEARCH , small-animal models are critical for the development of effective therapeutic strategies. The majority of rodent studies involve mice, owing in large part to the ability to readily manipulate the murine genome. Mice are now used routinely to probe the effects of individual genes on tumor growth and development and in preclinical studies of new therapeutics. Methods to accurately monitor tumor growth and response to therapy in vivo are a key to the effectiveness of these preclinical investigations. This is particularly true for brain tumors. Intracranial models of brain tumors, in which tumor cell lines are implanted directly into the brain [1] [2] [3] [4] or mice that are genetically engineered to spontaneously initiate tumor growth, [5] [6] [7] are the most clinically relevant because the tumor grows directly within the microenvironment of the brain itself. However, tool for this animal selection. MRI can also play an important role as solid tumors of 1 to 2 mm in diameter can be detected and their growth measured quantitatively. Although a number of studies have suggested a strong correlation between bioluminescence measurements and magnetic resonance-based calculations of tumor volumes, 3, 4, 30, 32 only a small number of studies comparing BLI and MRI for characterizing tumor growth and response to therapy have been described. 3, 4 A second important factor in the success of smallanimal preclinical studies is having a surrogate, in vivo, marker for both tumor growth and for tumor regression in response to successful therapeutic interventions. Many investigators have suggested that BLI would be useful for testing investigational therapeutic agents. However, this use is dependent on confi rming that stabilization or regression of the BLI signal corresponds to a stabilization or diminution of tumor size.
In our laboratory, we are particularly interested in the diagnosis, staging, and treatment of high-grade brain tumors and have signifi cant experience with malignant murine brain tumors using the DBT-FG-cell model. Although not a perfect model of human glioblastoma, the DBT-FG-cell model has imaging, growth, and histopathologic features that are similar to high-grade gliomas, 1 shows some degree of cellular infi ltration, and displays genetic changes (eg, loss of p53 and PTEN ) similar to those seen in human tumors. In our experience with this model, we have observed specifi c instances in which BLI data did not directly correlate with corresponding anatomic MRIs. In this work, we describe a comprehensive, combined MRI-BLI study of tumor growth in the DBT-FG-cell model. Based on this study, we identify cautions that must be exercised in the interpretation of BLI or MRI data alone in the context of tumor growth and therapeutic response and describe a cost-effective, multimodality imaging strategy for selecting cohorts of animals with similar tumor growth patterns.
Materials and Methods

Luciferase-Expressing Tumor Cell Line
The DBT glioblastoma cell line was originally generated from an intracranial tumor induced in an adult mouse after intracerebral injection of a Rous sarcoma virus. The DBT cell line used in these experiments was generously donated by Dr. Michael Lai, Department of Microbiology, University of Southern California. Transduction and maintenance of DBT-FG cells, a derivative tumor cell line transduced with a lentivirus for stable expression of both fi refl y luciferase and green fl uorescent protein (GFP), have been described. 33, 34 Tumor cells were passaged for up to 8 weeks, after which fresh cells were reinnoculated from frozen stock into media and cultured to minimize loss of the luciferase signal.
Intracranial Tumor Injections
Preparation of Cells for Injection
Feeding medium was aspirated from culture fl asks containing DBT-FG cells grown to approximately 70% confl uence. Cells were washed with Dulbecco's Modifi ed Eagle's Medium (DMEM), and then 3 mL of 0.5% trypsinethylenediaminetetraacetic acid was added over 1 minute. After the cells were suspended, trypsin was inactivated by adding 7 mL of DMEM containing 10% fetal calf serum. The suspended cells were centrifuged at 250 g for 10 minutes at 4°C and resuspended in 2 mL of DMEM. An aliquot of cells was aspirated, stained with trypan blue dye, and counted with a hemocytometer. The cells were recentrifuged and suspended in serum-free DMEM to a concentration of 10,000 DBT-FG cells/µL.
Animal Surgery
Adult female BALB/c mice weighing approximately 25 g were used in this study. All animal protocols were approved by the Washington University Division of Comparative Medicine and met or exceeded American Association for the Accreditation of Laboratory Animal Care International and National Institutes of Health standards. The mice were anesthetized by intraperitoneal injection of 25 mg/kg ketamine, 5 mg/kg xylazine, and 2.5 mg/kg acepromazine prior to intracranial implantation of DBT-FG cells. After a midline scalp incision, a craniostomy was created over the cortex with a 1 mm cutting burr. Mice were secured in a stereotactic frame, and 5 µL of the DBT-FG tumor cell suspension (Ϸ50,000 cells) was aspirated into a Hamilton syringe attached to the frame, which was then passed into the brain. Tumor cells were injected into the striatum at a site 2 mm lateral and 2 mm posterior to the bregma and 4 mm deep to the cortical surface. After the needle was removed, the craniostomy was sealed with bone wax and the scalp was closed with superglue. Following surgery, mice were housed in nonbarrier animal facilities for the duration of the imaging experiments. Although animals with large brain tumors were more likely to die under anesthesia than healthy animals, mice were successfully and routinely imaged at multiple time points with both MRI and BLI throughout this study.
In Vivo BLI
Mice were injected intraperitoneally with 150 mg/kg of D-luciferin in phosphate-buffered saline 10 minutes prior to imaging. Imaging was performed using a charge-coupled device camera (IVIS 100, Xenogen-Caliper, Alameda, CA; exposure times 1-120 s, binning 2-8, fi eld of view [FOV] 15 cm, f/stop 1, no fi lter). Mice were anesthetized with isofl urane (2% vaporized in O 2 ) prior to and during imaging. Total photon fl ux (photons/s) was measured from a fi xed region of interest over the skull using Living Image and IgorPro software (Wavemetrics, Portland, OR) as previously described. 35 
Magnetic Resonance Imaging
Images were collected in an Oxford Instruments (Oxford, UK) 4.7-Tesla magnet (33 cm, clear bore) equipped with 15 cm inner diameter, actively shielded gradient coils (maximum gradient 18 G/cm; rise time 200 µs). The magnet/gradients are interfaced with a Varian (Palo Alto, CA) INOVA console, and data were collected using a 1.5 cm OD surface coil (receive) and a 9 cm ID Helmholtz coil (transmit). Before the imaging experiments, mice were anesthe-
Mice were injected intraperitoneally with 500 µL Omniscan (Gadodiamide, GE Healthcare, Princeton, NJ) contrast agent, diluted 1:10 in sterile saline, 15 minutes prior to being placed in the magnet. 
Quantitative Assessment of Tumor Volume (MRI)
For MRI studies, tumor volumes were measured by manually segmenting tumors using either Varian's ImageBrowser software or the public domain program ImageJ (<http://rsbweb. nih.gov/ij>). T 2 -weighted images were sometimes used to help clarify tumor margins. Anatomic abnormalities such as hemorrhage, hydrocephalus, or tumor necrosis were noted, and their presence was correlated with optical signals.
Histologic Analysis
Following the last day of imaging, mice were heavily sedated with isofl urane and perfused with 4% paraformaldehyde. Brains were removed from the mice and placed in 4% paraformaldehyde for 24 hours at 4°C. The brains were next placed in 70% alcohol for 48 hours and then cut into 2 mm sections for paraffi n fi xation. The paraffi n embedded specimens were cut, again in the coronal plane, into 50 µm sections. These fi xed specimens were stained with hematoxylin and eosin and were correlated with corresponding MRIs.
Results and Discussion
MRI is effective for measuring tumor growth, and therapeutic response and calculations of intracranial tumor volumes from MRIs correlate well with postmortem tumor volumes. 11, 36 However, MRI is not well suited to high-throughput studies and cannot detect tumor growth early after implantation. For volumetric assays, BLI offers a valuable method for identifying tumors early after implantation, 37 monitoring tumor growth, 34 and measuring response to intervention. 38, 39 Recently, the use of BLI for monitoring the effects of antivascular therapy in a breast cancer xenograft model, emphasizing the importance of luciferin delivery to tumor, was described. 40 Previous studies have also documented the linearity of BLI signal measured in vivo with respect to luciferase activity measured ex vivo. 34, 41 Compared with MRI or other methods for assessing tumor growth in vivo, BLI experiments are quick and easy to perform and offer a relatively inexpensive and effi cient method for high-throughput studies.
In this study, four groups of 10 mice each were implanted with 50,000 DBT-FG cells constitutively expressing fi refl y luciferase and then serially imaged using both MRI and BLI. The fi rst objective of the study, using the fi rst 20 mice, was to establish a correlation between bioluminescence signal and tumor volume using BLI and MRI over the time course of tumor growth. The second objective, using the second 20 mice, was to determine whether early bioluminescence signal accurately predicted subsequent (exponential) tumor growth and whether, conversely, those tumors showing exponential growth on MRI had longitudinal BLI signals that corresponded well to the magnetic resonance growth curves.
Although the majority of the mice showed excellent correlation between tumor volumes as measured by MRI and quantitative BLI signal, particularly at the early stages of tumor growth ( Figure 1 ), we found that at the extremes (very low BLI signal or very large tumor volumes), this correlation was much weaker. We identifi ed two particular situations in which mice without MRI-visible tumors had a strong BLI signal: mice with hydrocephalus ( Figure 2 ) and mice with intracranial hemorrhage ( Figure 3 ). Signifi cant tumor was not visible on MRIs of any of these animals. Mice ( n = 2) with hydrocephalus survived to 13 and 14 days post-tumor injection and had BLI growth curves consistent with exponential tumor growth. These mice deteriorated clinically in a similar fashion to animals with growing tumor. One mouse with an intracranial hematoma failed to deteriorate clinically and displayed a BLI signal that initially increased exponentially in intensity and declined in the late stages of the experiment.
We noticed an additional discrepancy between BLI signal and MRI measurement of tumor growth. At late stages of growth in animals with a growing solid tumor, MRI measurements showed steadily increasing volumes, whereas the optical signal tended to plateau. A similar effect, with in vivo BLI signal plateauing in large tumors, was observed in a study of mouse liver. 42 This late plateau is seen in the correlations between BLI signal and tumor volumes in Figure 1 . A representative example of this discordance is demonstrated longitudinally and anatomically in Figure 4 . This change is attributed to development of hemorrhage and necrosis within the tumor bed, a fi nding that was seen on both anatomic MRIs ( Figure 4 , C and D) and in histologic specimens ( Figure 5 ). Thus, BLI may refl ect viable cell mass, 34, 41, 43, 44 whereas MRI refl ects overall tumor volume.
One of the major strengths of preclinical studies in animals is the ability to perfuse organs and perform subsequent histology and immunohistochemistry (IHC) staining. Such correlative histology/IHC provides insight into the cellular changes occurring within tumor tissue and can help validate the results of imaging studies. Figure 5 illustrates examples of hematoxylin-eosin stains from brains imaged in these studies. Figure 5A shows tissue from a region of brain tumor; the tissue is characterized by high cellular density and several unusually large nuclei. This highly cellular tumor, with Figure 1 . Bioluminescence imaging (BLI) optical signal intensities are plotted versus their corresponding magnetic resonancedetermined tumor volumes (in murine brain tumors generated by injection of luciferase-bearing DBT-FG cells). While in the early stages of tumor growth, when tumors are less than 40 mm 3 , there is a strong correlation between tumor volume and BLI signal ( R 2 = .78); a signifi cant loss of this correlation is seen once the tumors grow beyond 40 mm 3 ( R 2 = .13). numerous, densely packed viable cells, is the setting where BLI signal would likely correlate well with magnetic resonance volume. The presence of intraventricular tumor is illustrated in Figure 5B . Growth of intraventricular tumor, either within the cerebrospinal fl uid as isolated cells or in small clusters causing ventricular obstruction and hydrocephalus, offers an anatomic and biologic explanation for the high BLI signal in the absence of intraparenchymal tumor seen in Figure 2 . Figure 5C shows tissue from a hemorrhagic region of brain, whereas necrotic tumor tissue is illustrated in Figure 5D . Each of these changes occurs late in the time course of tumor growth and may show focally enhanced absorption of BLI signal or indicate a loss of viable tumor cells.
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In a combined BLI-MRI study using another cohort of 20 mice, we tested the hypothesis that the presence and growth of BLI signals at early time points would be predictive of subsequent exponential tumor growth and that those tumors that grew in a standard exponential pattern would all have BLI signals that longitudinally matched that growth. Serial BLI and MRI experiments were performed on all mice. After tumors had grown to the maximally tolerated size, animals whose magnetic resonance-detected tumor growth was exponential were identifi ed. The optical signals for each of these animals were reviewed retrospectively. We had expected that mice with exponential tumor growth by MRI would have optical growth curves similar to one another. However, we found a few examples of spontaneous diminution of luciferase signal (a fi nding noted in previous studies of luciferase tumor models 45 ) that confounded our ability to reliably predict tumor growth from optical signal curves alone ( Figure 6 ). Although the number of animals with spontaneous regression of BLI signal was small ( n = 2), if this study had been a preclinical therapeutic response trial, these two animals, with progressive exponential growth in tumor size, would have, by BLI alone, been described as "responders." This observation demonstrates the value of using BLI and MRI in combination to best evaluate tumor regression in preclinical therapeutic trials.
Our successes in using combined BLI and MRI to measure tumor growth, along with the complementary information available with each imaging method, lead us to suggest a strategy for combining these two imaging modalities to identify and select animals for preclinical therapeutic studies. This multimodality strategy, designed to identify animals with similar tumor growth rates while limiting the impact of confounding factors such as hemorrhage, necrosis, and loss of luciferase signal, is summarized in the fl owchart in Figure 7 . Methodologically, we propose beginning by injecting a group of animals larger than the intended study sample size with a luciferase-bearing tumor cell line (eg, for an intended sample size of 6 to 8 mice, we typically inject 10 mice). Animals are assessed shortly after implantation and serially using BLI semiweekly or at appropriate time points based on the anticipated growth rate of the chosen tumor cell line. Regular measurement of BLI signal permits us to match photon outputs across mice, thereby allowing us to select cohorts of animals with similar amounts of viable tumor cell mass. In addition, all animals with a visible BLI signal undergo standard anatomic MRI early in the course of the study to identify confounding anatomic features such as hemorrhage or hydrocephalus. Following multiple BLIs and the single MRI, animals with abnormal tumor growth patterns or unusual anatomic fi ndings are excluded from . Bioluminescence imaging signal from a longitudinal study of 10 mice, all of whom, based on serial anatomic magnetic resonance imaging studies, showed exponential growth of solid tumor without confounding hemorrhage or hydrocephalus. Each symbol represents data for one of the ten mice in this study. Two outliers, whose tumor growth was signifi cant but whose optical signal declined early in the time course of growth, are noted. subsequent preclinical experiments. In our experience, approximately 20% of animals initially injected with tumor cells would be eliminated from later preclinical studies by the strategy outlined in Figure 7 . The timing of the steps suggested in Figure 7 will vary depending on the growth rate of the tumor cell line, the number of cells injected, and the elapsed time following injection of cells prior to initiation of treatment. In our previously published imaging study of carmustine chemotherapy in DBT-FG-cell tumors, tumors typically had grown to a volume of 20 to 30 mm 3 at the time that treatment was initiated. 1 The combination of anatomic MRI and BLI summarized in Figure 7 provides a multidisciplinary approach for selecting a subset of animals with similar patterns of tumor growth for subsequent imaging or therapeutic studies while eliminating the confounding effects of hemorrhage or hydrocephalus. Although we performed this study using the DBT-FG-cell tumor model, the methodology can be readily extended to include other glioma cell lines (eg, U87 cells) that can be modifi ed to stably express luciferase. 34 Although performing the MRI adds a step to these studies, we have found that this additional set of scans does not signifi cantly complicate the overall logistics of these experiments, nor, in centers where small-animal imaging is available, does it add dramatically to the cost. Indeed, by enabling efficient selection of cohorts of animals with similar tumor growth that are free of confounding anatomic features, we predict that this multimodal approach will ultimately decrease both the number of animals and the number of scans needed to obtain meaningful results. Further, we suggest that adding periodic MRIs to longitudinal BLI at later stages of therapeutic studies will increase the role of imaging in assessing treatment effi cacy by allowing measurement of both remaining viable tumor cell mass (BLI) and residual tumor volume/mass, including intratumoral regions of hemorrhage and necrosis (MRI). The two imaging modalities have the capacity to function synergistically, and each can offset the potential challenges of the other: BLI can identify early tumor growth and improve effi ciency, and MRI can identify anatomic anomalies (hemorrhage, hydrocephalus, necrosis) and catch the rare instances of spontaneous BLI diminution. The combination of the two modalities will further increase the likelihood that useful information will be gleaned from imaging-based preclinical studies, allowing effi cient translation to stage 1 human clinical trials. 
